Quest Diagnostics and Hologic, Inc., have entered into a strategic alliance to more broadly offer testing based on Hologic’s APTIMA family of products, as well as to co-develop and promote advanced diagnostic solutions to improve women’s health.
The companies will focus primarily on clinical areas critical to the health of women. Quest Diagnostics will transition to a broader offering of services based on Hologic’s APTIMA products, which include FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea, and trichomonas vaginalis. In addition, Quest Diagnostics will continue to utilize Hologic’s line of ThinPrep liquid-based cytology products.
Quest Diagnostics will also continue to offer Hologic’s APTIMA HPV mRNA-based assay nationally. The APTIMA HPV assay detects messenger RNA overexpressed from two viral oncogenes that are integral to the development of cervical cancer. Hologic's APTIMA HPV assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens.
The companies will also explore opportunities to develop and expand access to new diagnostic solutions for women’s health. In addition, they will implement programs to advance women’s health issues with medical associations and patient advocacy groups and to sponsor research. Read more about women’s health solutions provided by Hologic and diagnostic services provide by Quest.